Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Milveterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 19/20 | 0.98 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.98 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Milveterol SCHEMBL2953766 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL2014100 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL2953771 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL2014102 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL2953768 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL168972 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL185356 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL265694 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL4385046 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3 | |
| Milveterol SCHEMBL29448200 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7846973-B2 | Chemical process and new crystalline form | THERAVANCE, INC. (US) | 2010-12-07 | — | — | US | claimed |
| US-20100063157-A1 | CHEMICAL PROCESS AND NEW CRYSTALLINE FORM | THERAVANCE BIOPHARMA R&D IP, LLC | 2010-03-11 | — | — | US | claimed |
| US-7557247-B2 | Crystalline form of β2 adrenergic receptor agonist | THERAVANCE, INC. (US) | 2009-07-07 | — | — | US | claimed |
| US-20070155990-A1 | Crystalline form of beta2 adrenergic receptor agonist | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-07-05 | — | — | US | claimed |
| JP-2007500233-A | — | — | 2007-01-11 | — | — | JP | claimed |
| EP-1641744-A2 | CRYSTALLINE FORM OF B2 ADRENERGIC RECEPTOR AGONIST | Theravance, Inc. (US) | 2006-04-05 | — | — | EP | claimed |
| WO-2004106279-A2 | CRYSTALLINE FORM OF β2 ADRENERGIC RECEPTOR AGONIST | THERAVANCE, INC. (US) | 2004-12-09 | — | — | WO | claimed |
| US-20040248985-A1 | Crystalline form of beta2 adrenergic receptor agonist | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-12-09 | — | — | US | claimed |
| US-12636447-B2 | Dry powder inhaler with an adherence/compliance monitor | VECTURA DELIVERY DEVICES LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| US-12491156-B2 | Carrier particles for dry powder formulations for inhalation | CHIESI FARMACEUTICI S.P.A. (IT) | 2025-12-09 | — | — | US | disclosed |
| US-12427270-B2 | Inhaler for use with a compliance monitor | VECTURA DELIVERY DEVICES LIMITED (GB) | 2025-09-30 | — | — | US | disclosed |
| EP-4340915-B1 | ADHERENCE MONITOR FOR A DRY POWDER INHALER | VECTURA DELIVERY DEVICES LTD (GB) | 2025-03-05 | — | — | EP | disclosed |
| EP-4333951-B1 | UNIT DOSE DRY POWDER INHALER | VECTURA DELIVERY DEVICES LTD (GB) | 2024-12-11 | — | — | EP | disclosed |
| EP-4114743-B1 | PROCESS FOR MANUFACTURING A BLISTER STRIP FOR A DRY POWDER INHALER | VECTURA DELIVERY DEVICES LTD (GB) | 2024-11-13 | — | — | EP | disclosed |
| EP-1730104-A1 | CHEMICAL PROCESS AND NEW CRYSTALLINE FORM | GLAXO GROUP LIMITED (GB) | 2006-12-13 | — | — | EP | disclosed |
| EP-1641744-A2 | CRYSTALLINE FORM OF B2 ADRENERGIC RECEPTOR AGONIST | Theravance, Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005095328-A1 | CHEMICAL PROCESS AND NEW CRYSTALLINE FORM | GLAXO GROUP LIMITED (GB) | 2005-10-13 | — | — | WO | disclosed |
| US-20050113411-A1 | Amino-substituted ethylamino beta2 adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-05-26 | — | — | US | disclosed |
| WO-2004106279-A2 | CRYSTALLINE FORM OF β2 ADRENERGIC RECEPTOR AGONIST | THERAVANCE, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040248985-A1 | Crystalline form of beta2 adrenergic receptor agonist | THERAVANCE BIOPHARMA R&D IP, LLC | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063157-A1 | CHEMICAL PROCESS AND NEW CRYSTALLINE FORM | ADRA2C, ADRB2, AGTR2 | ADRB2 2/4885ADRB1 6/4885ADRB3 8/4885 |
| US-20040248985-A1 | Crystalline form of beta2 adrenergic receptor agonist | ADRB2, ADRA2C, ADRA2A | ADRB2 1/4885ADRB1 4/4885ADRB3 6/4885 |
| US-20050113411-A1 | Amino-substituted ethylamino beta2 adrenergic receptor agonists | ADRB2, ADRB1, ADRA2A | ADRB2 1/4885ADRB1 2/4885ADRB3 6/4885 |
| US-20070155990-A1 | Crystalline form of beta2 adrenergic receptor agonist | ADRB2, ADRA2C, ADRA2A | ADRB2 1/4885ADRB1 4/4885ADRB3 6/4885 |
| US-12636447-B2 | Dry powder inhaler with an adherence/compliance monitor | CHRM2, CHRM1, CHRM4 | ADRB2 199/4885ADRB1 557/4885ADRB3 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.